Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
To read the full story
Related Article
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
REGULATORY
- Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
November 16, 2026
- Pharma Calls for Drug Price Hikes, Govt Purchases to Spur MCM Investment
November 16, 2026
- Stable Supply Drives Japan’s Generic Drug Delistings: Jiho Tally
November 16, 2026
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
- New Radiopharma Action Plan Urges Domestic CDMO Development: Draft
November 13, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





